All News

As the incidence of young-onset colorectal cancer continues to rise, the findings from a large Taiwanese population-based study support lowering the age for initial screening.

New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

RAD 2025: Peter Lio, MD, discussed the benefits of disease-specific meetings, the evolving AD landscape, and why continuity across sessions enhances clinician education.

The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.

EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.

Using FMT over standard-of-care therapy may significantly reduce antibiotic use and well-known harms, including antibiotic resistance, study authors noted.

For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.

Among 2000 US adults, a new survey found consumers prioritize trust and recommendations over brand loyalty in health tracking devices, prizing accuracy and reliability.

AUD affects 15 million Americans, with men nearly 2 times more vulnerable to the disease vs women. Are you tracking signs and symptoms in your patients?

RAD 2025: Glick spoke to Patient Care about the similarities between TSW and a flare of atopic dermatitis as well as specific signs now being identified d as characteristic.

The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.

The American College of Lifestyle Medicine recently published "that guideline," and lead author Richard Rosenfeld, MD, MPH, MBA, says the timing was right.

Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.

Authors say their findings support the accumulating evidence that late-life mood disorders may be a prodromal manifestation of dementia vs a risk factor alone.

Both oral and subcutaneous formulations of the long-acting GLP-1 and amylin receptor agonist move into stage 3 clinical trials following positive feedback from regulators.

mRNA1345 (mResvia) is now indicated for adults aged 18 to 59 years with underlying conditions including cardiovascular, respiratory, and endocrine disorders.

Your daily dose of the clinical news you may have missed.

At RAD 2025, pediatric dermatologist Elizabeth Swanson, MD, discussed the value of focused AD education and anticipated label expansions for several treatments.